Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927690 · ClinicalTrials.gov registry record · Phase 2
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT03927690 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 91 participants.
The verdict
NCT03927690, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
Interventions
- DRUG Lucentis
- DRUG LKA651
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927690
The ClinicalTrials.gov registry entry for NCT03927690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lucentis is the first listed.
NCT03927690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03927690 about?
NCT03927690 is a clinical study titled "Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema". The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
What is the current status of trial NCT03927690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2019-05-24. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT03927690?
The interventions under investigation include: Lucentis (DRUG), LKA651 (DRUG).
Who is sponsoring clinical trial NCT03927690?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.